Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6ATAC32P is classified as a pseudogene related to the small nuclear RNA known as U6atac, but does not produce a functional protein or snRNA[3]. RNU6ATAC32P is a processed pseudogene derived from the U6atac small nuclear RNA gene, annotated in the human genome (HGNC: 46931, NCBI Gene: 106479556, Ensembl: ENSG00000251835)[3]. The U6atac snRNA is part of the minor spliceosome, responsible for catalyzing the removal of rare “minor” introns in a select group of highly conserved genes, playing a role in post-transcriptional gene regulation and cell response to stress[1]. However, RNU6ATAC32P is not itself a functional RNA and does not contribute to minor spliceosome activity; it exists in the genome as a non-functional, duplicated sequence. Pseudogenes like RNU6ATAC32P do not typically serve as drug targets or biomarkers. There is no evidence supporting RNU6ATAC32P involvement in cellular processes, disease mechanisms, or as a therapeutic target[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 32, pseudogene (RNU6ATAC32P).